Loading…
Differentiation and Regulation of T H Cells: A Balancing Act for Cancer Immunotherapy
Current success of immunotherapy in cancer has drawn attention to the subsets of T cells in the tumor which are critical for activation of anti-tumor response either directly by themselves or by stimulating cytotoxic T cell activity. However, presence of immunosuppressive pro-tumorigenic T subsets i...
Saved in:
Published in: | Frontiers in immunology 2021-05, Vol.12, p.669474 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Current success of immunotherapy in cancer has drawn attention to the subsets of T
cells in the tumor which are critical for activation of anti-tumor response either directly by themselves or by stimulating cytotoxic T cell activity. However, presence of immunosuppressive pro-tumorigenic T
subsets in the tumor milieu further contributes to the complexity of regulation of T
cell-mediated immune response. In this review, we present an overview of the multifaceted positive and negative effects of T
cells, with an emphasis on regulation of different T
cell subtypes by various immune cells, and how a delicate balance of contradictory signals can influence overall success of cancer immunotherapy. We focus on the regulatory network that encompasses dendritic cell-induced activation of CD4
T
1 cells and subsequent priming of CD8
cytotoxic T cells, along with intersecting anti-inflammatory and pro-tumorigenic T
2 cell activity. We further discuss how other tumor infiltrating immune cells such as immunostimulatory T
9 and T
cells, immunosuppressive T
cells, and the duality of T
17 function contribute to tip the balance of anti- vs pro-tumorigenic T
responses in the tumor. We highlight the developing knowledge of CD4
T
1 immune response against neoantigens/oncodrivers, impact of current immunotherapy strategies on CD4
T
1 immunity, and how opposing action of T
cell subtypes can be explored further to amplify immunotherapy success in patients. Understanding the nuances of CD4
T
cells regulation and the molecular framework undergirding the balancing act between anti- vs pro-tumorigenic T
subtypes is critical for rational designing of immunotherapies that can bypass therapeutic escape to maximize the potential of immunotherapy. |
---|---|
ISSN: | 1664-3224 |
DOI: | 10.3389/fimmu.2021.669474 |